{"id":4828,"date":"2026-05-20T23:07:02","date_gmt":"2026-05-20T23:07:02","guid":{"rendered":"https:\/\/fehv.org\/?p=4828"},"modified":"2026-05-20T23:07:07","modified_gmt":"2026-05-20T23:07:07","slug":"study-new-drug-treatment-hepatitis-b","status":"publish","type":"post","link":"https:\/\/fehv.org\/en\/study-new-drug-treatment-hepatitis-b\/","title":{"rendered":"Study of a new drug for the treatment of Hepatitis B"},"content":{"rendered":"\n<p style=\"font-size:18px\">It is estimated that around 257 million people worldwide suffer from chronic hepatitis B virus infection. This infection can lead to liver cirrhosis and liver cancer over the years if left untreated. Effective antiviral drugs exist to prevent the damage caused by this virus in the liver. Antiviral therapies such as nucleotide analogues (entecavir, tenofovir) effectively suppress viral DNA, but reactivation occurs when treatment is discontinued. In addition, approximately 15% to 40% of <strong><a href=\"https:\/\/fehv.org\/en\/diseases\/hepatitis-b\/\" type=\"page\" id=\"1602\">hepatitis B<\/a><\/strong> patients treated with nucleotide analogues fail to completely inhibit the virus, leaving DNA in the blood. On the other hand, pegylated interferon alpha has an efficacy of 25% but with notable side effects. This has led to research into the use of new drugs in the treatment of hepatitis B.\u00a0<\/p>\n\n\n\n<h2 class=\"wp-block-heading mt-5 mb-4\" id=\"h-analysis-of-the-study-carried-out-for-the-treatment\"><strong>Analysis of the study carried out for the treatment<\/strong><\/h2>\n\n\n\n<p style=\"font-size:18px\">In this regard, a study has been published in the <strong><a href=\"https:\/\/www.thelancet.com\/\" type=\"link\" id=\"https:\/\/www.thelancet.com\/\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">Lancet journal<\/a><\/strong> using a new drug (GST-HG141), an inhibitor of hepatitis B, in patients who did not fully respond to treatment with nucleotide analogues. The study included 90 patients with hepatitis B, divided into three groups of 30, and for six months they were administered GST-HG141 at different doses: the first group (group I) received a low dose (50 mg), the second (group II) a high dose (100 mg), and the third (group III) placebo, with all three groups continuing treatment with nucleotide analogues. <\/p>\n\n\n\n<p style=\"font-size:18px\">Of all the patients included in the study, 80 completed treatment and follow-up (group I = 25, group II = 27, and group III = 28). The tolerance of this new drug was good. The response, considered as the disappearance of viral DNA, was as follows: group I = 84%, group II = 81%, and group III = 32%. In summary, the study confirms that this drug (GST-HG141) appears effective against hepatitis B virus in patients with a partial response to current treatments.<\/p>\n\n\n\n<p style=\"font-size:18px\">The conclusion we can reach is that this drug may be useful in the treatment of hepatitis B virus infection. However, in the opinion of <strong><a href=\"https:\/\/fehv.org\/en\/especialista\/dr-vicente-carreno\/\">Dr. Carre\u00f1o<\/a><\/strong> and his team, further studies are needed, extending the duration of treatment (not just to six months) and not focusing the studies on the Chinese population.<\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"A study suggests GST-HG141 may become an effective new hepatitis B treatment for patients with incomplete response to current antiviral therapies.","protected":false},"author":1,"featured_media":4825,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1621,621,624],"tags":[],"class_list":["post-4828","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-hepatitis-b-2","category-news","category-treatments"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.6 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Study of a new drug for the treatment of Hepatitis B - Cl\u00ednica FEHV<\/title>\n<meta name=\"description\" content=\"The new hepatitis B treatment GST-HG141 shows promising antiviral efficacy in patients with partial response to current therapies.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/fehv.org\/en\/study-new-drug-treatment-hepatitis-b\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Study of a new drug for the treatment of Hepatitis B\" \/>\n<meta property=\"og:description\" content=\"The new hepatitis B treatment GST-HG141 shows promising antiviral efficacy in patients with partial response to current therapies.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/fehv.org\/en\/study-new-drug-treatment-hepatitis-b\/\" \/>\n<meta property=\"og:site_name\" content=\"Cl\u00ednica FEHV\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/clinicaFEHV\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-20T23:07:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-20T23:07:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/fehv.org\/wp-content\/uploads\/2026\/05\/nuevo_farmaco_hepatitis_b.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1408\" \/>\n\t<meta property=\"og:image:height\" content=\"768\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"ifranco\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"ifranco\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/fehv.org\\\/en\\\/study-new-drug-treatment-hepatitis-b\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/fehv.org\\\/en\\\/study-new-drug-treatment-hepatitis-b\\\/\"},\"author\":{\"name\":\"ifranco\",\"@id\":\"https:\\\/\\\/fehv.org\\\/#\\\/schema\\\/person\\\/5e92ddd4a04516dab21fb5b6fa90b777\"},\"headline\":\"Study of a new drug for the treatment of Hepatitis B\",\"datePublished\":\"2026-05-20T23:07:02+00:00\",\"dateModified\":\"2026-05-20T23:07:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/fehv.org\\\/en\\\/study-new-drug-treatment-hepatitis-b\\\/\"},\"wordCount\":355,\"publisher\":{\"@id\":\"https:\\\/\\\/fehv.org\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/fehv.org\\\/en\\\/study-new-drug-treatment-hepatitis-b\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/fehv.org\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/nuevo_farmaco_hepatitis_b.png\",\"articleSection\":[\"Hepatitis B\",\"News\",\"Treatments\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/fehv.org\\\/en\\\/study-new-drug-treatment-hepatitis-b\\\/\",\"url\":\"https:\\\/\\\/fehv.org\\\/en\\\/study-new-drug-treatment-hepatitis-b\\\/\",\"name\":\"Study of a new drug for the treatment of Hepatitis B - Cl\u00ednica FEHV\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/fehv.org\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/fehv.org\\\/en\\\/study-new-drug-treatment-hepatitis-b\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/fehv.org\\\/en\\\/study-new-drug-treatment-hepatitis-b\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/fehv.org\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/nuevo_farmaco_hepatitis_b.png\",\"datePublished\":\"2026-05-20T23:07:02+00:00\",\"dateModified\":\"2026-05-20T23:07:07+00:00\",\"description\":\"The new hepatitis B treatment GST-HG141 shows promising antiviral efficacy in patients with partial response to current therapies.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/fehv.org\\\/en\\\/study-new-drug-treatment-hepatitis-b\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/fehv.org\\\/en\\\/study-new-drug-treatment-hepatitis-b\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/fehv.org\\\/en\\\/study-new-drug-treatment-hepatitis-b\\\/#primaryimage\",\"url\":\"https:\\\/\\\/fehv.org\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/nuevo_farmaco_hepatitis_b.png\",\"contentUrl\":\"https:\\\/\\\/fehv.org\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/nuevo_farmaco_hepatitis_b.png\",\"width\":1408,\"height\":768,\"caption\":\"Grupo de investigadores en laboratorio - Imagen generada por IA\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/fehv.org\\\/en\\\/study-new-drug-treatment-hepatitis-b\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/fehv.org\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Study of a new drug for the treatment of Hepatitis B\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/fehv.org\\\/#website\",\"url\":\"https:\\\/\\\/fehv.org\\\/\",\"name\":\"Cl\u00ednica FEHV\",\"description\":\"Web de la Cl\u00ednica de la Fundaci\u00f3n para el Estudio de las Hepatitis Virales\",\"publisher\":{\"@id\":\"https:\\\/\\\/fehv.org\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/fehv.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/fehv.org\\\/#organization\",\"name\":\"Fundaci\u00f3n para el Estudio de las Hepatitis Virales - FEHV\",\"url\":\"https:\\\/\\\/fehv.org\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/fehv.org\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/fehv.org\\\/wp-content\\\/uploads\\\/2021\\\/03\\\/logo_fib-4.png\",\"contentUrl\":\"https:\\\/\\\/fehv.org\\\/wp-content\\\/uploads\\\/2021\\\/03\\\/logo_fib-4.png\",\"width\":47,\"height\":73,\"caption\":\"Fundaci\u00f3n para el Estudio de las Hepatitis Virales - FEHV\"},\"image\":{\"@id\":\"https:\\\/\\\/fehv.org\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/clinicaFEHV\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/fehv.org\\\/#\\\/schema\\\/person\\\/5e92ddd4a04516dab21fb5b6fa90b777\",\"name\":\"ifranco\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a420f8de9a7d1d8c59aac0d97d817361feea70d815889a4d807921618ae04918?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a420f8de9a7d1d8c59aac0d97d817361feea70d815889a4d807921618ae04918?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a420f8de9a7d1d8c59aac0d97d817361feea70d815889a4d807921618ae04918?s=96&d=mm&r=g\",\"caption\":\"ifranco\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Study of a new drug for the treatment of Hepatitis B - Cl\u00ednica FEHV","description":"The new hepatitis B treatment GST-HG141 shows promising antiviral efficacy in patients with partial response to current therapies.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/fehv.org\/en\/study-new-drug-treatment-hepatitis-b\/","og_locale":"en_US","og_type":"article","og_title":"Study of a new drug for the treatment of Hepatitis B","og_description":"The new hepatitis B treatment GST-HG141 shows promising antiviral efficacy in patients with partial response to current therapies.","og_url":"https:\/\/fehv.org\/en\/study-new-drug-treatment-hepatitis-b\/","og_site_name":"Cl\u00ednica FEHV","article_publisher":"https:\/\/www.facebook.com\/clinicaFEHV\/","article_published_time":"2026-05-20T23:07:02+00:00","article_modified_time":"2026-05-20T23:07:07+00:00","og_image":[{"width":1408,"height":768,"url":"https:\/\/fehv.org\/wp-content\/uploads\/2026\/05\/nuevo_farmaco_hepatitis_b.png","type":"image\/png"}],"author":"ifranco","twitter_card":"summary_large_image","twitter_misc":{"Written by":"ifranco","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/fehv.org\/en\/study-new-drug-treatment-hepatitis-b\/#article","isPartOf":{"@id":"https:\/\/fehv.org\/en\/study-new-drug-treatment-hepatitis-b\/"},"author":{"name":"ifranco","@id":"https:\/\/fehv.org\/#\/schema\/person\/5e92ddd4a04516dab21fb5b6fa90b777"},"headline":"Study of a new drug for the treatment of Hepatitis B","datePublished":"2026-05-20T23:07:02+00:00","dateModified":"2026-05-20T23:07:07+00:00","mainEntityOfPage":{"@id":"https:\/\/fehv.org\/en\/study-new-drug-treatment-hepatitis-b\/"},"wordCount":355,"publisher":{"@id":"https:\/\/fehv.org\/#organization"},"image":{"@id":"https:\/\/fehv.org\/en\/study-new-drug-treatment-hepatitis-b\/#primaryimage"},"thumbnailUrl":"https:\/\/fehv.org\/wp-content\/uploads\/2026\/05\/nuevo_farmaco_hepatitis_b.png","articleSection":["Hepatitis B","News","Treatments"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/fehv.org\/en\/study-new-drug-treatment-hepatitis-b\/","url":"https:\/\/fehv.org\/en\/study-new-drug-treatment-hepatitis-b\/","name":"Study of a new drug for the treatment of Hepatitis B - Cl\u00ednica FEHV","isPartOf":{"@id":"https:\/\/fehv.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/fehv.org\/en\/study-new-drug-treatment-hepatitis-b\/#primaryimage"},"image":{"@id":"https:\/\/fehv.org\/en\/study-new-drug-treatment-hepatitis-b\/#primaryimage"},"thumbnailUrl":"https:\/\/fehv.org\/wp-content\/uploads\/2026\/05\/nuevo_farmaco_hepatitis_b.png","datePublished":"2026-05-20T23:07:02+00:00","dateModified":"2026-05-20T23:07:07+00:00","description":"The new hepatitis B treatment GST-HG141 shows promising antiviral efficacy in patients with partial response to current therapies.","breadcrumb":{"@id":"https:\/\/fehv.org\/en\/study-new-drug-treatment-hepatitis-b\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/fehv.org\/en\/study-new-drug-treatment-hepatitis-b\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/fehv.org\/en\/study-new-drug-treatment-hepatitis-b\/#primaryimage","url":"https:\/\/fehv.org\/wp-content\/uploads\/2026\/05\/nuevo_farmaco_hepatitis_b.png","contentUrl":"https:\/\/fehv.org\/wp-content\/uploads\/2026\/05\/nuevo_farmaco_hepatitis_b.png","width":1408,"height":768,"caption":"Grupo de investigadores en laboratorio - Imagen generada por IA"},{"@type":"BreadcrumbList","@id":"https:\/\/fehv.org\/en\/study-new-drug-treatment-hepatitis-b\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/fehv.org\/en\/"},{"@type":"ListItem","position":2,"name":"Study of a new drug for the treatment of Hepatitis B"}]},{"@type":"WebSite","@id":"https:\/\/fehv.org\/#website","url":"https:\/\/fehv.org\/","name":"Cl\u00ednica FEHV","description":"Web de la Cl\u00ednica de la Fundaci\u00f3n para el Estudio de las Hepatitis Virales","publisher":{"@id":"https:\/\/fehv.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/fehv.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/fehv.org\/#organization","name":"Fundaci\u00f3n para el Estudio de las Hepatitis Virales - FEHV","url":"https:\/\/fehv.org\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/fehv.org\/#\/schema\/logo\/image\/","url":"https:\/\/fehv.org\/wp-content\/uploads\/2021\/03\/logo_fib-4.png","contentUrl":"https:\/\/fehv.org\/wp-content\/uploads\/2021\/03\/logo_fib-4.png","width":47,"height":73,"caption":"Fundaci\u00f3n para el Estudio de las Hepatitis Virales - FEHV"},"image":{"@id":"https:\/\/fehv.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/clinicaFEHV\/"]},{"@type":"Person","@id":"https:\/\/fehv.org\/#\/schema\/person\/5e92ddd4a04516dab21fb5b6fa90b777","name":"ifranco","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a420f8de9a7d1d8c59aac0d97d817361feea70d815889a4d807921618ae04918?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a420f8de9a7d1d8c59aac0d97d817361feea70d815889a4d807921618ae04918?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a420f8de9a7d1d8c59aac0d97d817361feea70d815889a4d807921618ae04918?s=96&d=mm&r=g","caption":"ifranco"}}]}},"_links":{"self":[{"href":"https:\/\/fehv.org\/en\/wp-json\/wp\/v2\/posts\/4828","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/fehv.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/fehv.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/fehv.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/fehv.org\/en\/wp-json\/wp\/v2\/comments?post=4828"}],"version-history":[{"count":2,"href":"https:\/\/fehv.org\/en\/wp-json\/wp\/v2\/posts\/4828\/revisions"}],"predecessor-version":[{"id":4830,"href":"https:\/\/fehv.org\/en\/wp-json\/wp\/v2\/posts\/4828\/revisions\/4830"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/fehv.org\/en\/wp-json\/wp\/v2\/media\/4825"}],"wp:attachment":[{"href":"https:\/\/fehv.org\/en\/wp-json\/wp\/v2\/media?parent=4828"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/fehv.org\/en\/wp-json\/wp\/v2\/categories?post=4828"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/fehv.org\/en\/wp-json\/wp\/v2\/tags?post=4828"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}